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Résumé en
anglais
In a previous study, we showed that cetuximab, a monoclonal antibody directed
towards epidermal growth factor receptor, could inhibit P-glycoprotein (P-gp), an
efflux protein of ATP-binding cassette family, and lead to an increased P-gp
substrate intracellular concentration. Cetuximab is given with irinotecan to patients
with metastasis colorectal cancer who did not respond to irinotecan-based therapy.
The mechanism of this successful clinical reversion remains unknown. As irinotecan
is a P-gp substrate, we tested here whether cetuximab could modify irinotecan
concentration in mice. Therefore, concentrations of irinotecan and of its active
metabolite SN-38 were measured by HPLC in plasma and tumour of mice bearing a
human colorectal carcinoma xenograft when irinotecan is given orally alone or after
a pretreatment with cetuximab. Pharmacokinetic analysis showed no significant
modification of irinotecan concentrations but a significant increase (1.7-fold) in
SN-38 AUCs in plasma and in tumour after a pretreatment with cetuximab. Those
results suggest that cetuximab influence irinotecan distribution into tissues
probably due to inhibition of P-gp. As SN-38 is 200-fold more potent than irinotecan,
cetuximab could reverse irinotecan resistance by an effect on its active metabolite.
Inhibiting SN-38 efflux by P-gp drug transporters in biliary system and tumour can
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